VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
CARY, N.C., June 12, 2023 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, in partnership with Smith Anderson, a Triangle-based full-service business...
Chiesi Farmaceutici`s Elfabrio (Pegunigalsidase alfa) Receives Approval in the Europe
2022 for Chiesi: The Group’s international growth continues
BOSTON, March 31, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced that Health Canada has approved FERRIPROX MR deferiprone extended-release tablets 1 000 mg for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate, or sickle cell disease (SCD) or other anemias.
Chiesi USA donates more than $830,000 to local communities and nonprofits in 2022
As a Certified B Corporationâ„¢, Chiesi deepens ASHP partnership to fund educational efforts designed to address the pharmacy technician shortage and support pharmaceutical professionals. CARY, N.C.,...
This cost-consequence analysis suggests selective early rescue surfactant administration strategies are associated with a lower healthcare burden in premature infants with RDS. CARY, N.C., Nov. ...
CARY, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has been ranked No. 15 among Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals.